Re-directed immunotherapy

Patent metadata

Field	Value
Publication number	US-11236131-B2
Application number	US-201916366240-A
Country	US
Kind code	B2
Filing date	Mar 27, 2019
Priority date	Mar 17, 2011
Publication date	Feb 1, 2022
Grant date	Feb 1, 2022

Abstract

The invention provides an agent for preventing or treating a condition characterised by the presence of unwanted cells, the agent comprising: (i) a targeting moiety that is capable of targeting to the unwanted cells; and (ii) a T cell antigen, wherein the T cell antigen can be released from the targeting moiety by selective cleavage of a cleavage site in the agent in the vicinity of the unwanted cells.

First claim

The invention claimed is:

1. An agent for retargeting T cells to solid tumor cells, the agent comprising:
(i) a targeting moiety that is capable of targeting to the solid tumor cells, wherein the targeting moiety is an antibody or antigen binding fragment thereof that binds a solid tumor antigen; and
(ii) more than one viral T cell epitope that each elicit an existing immune response in the subject and that each bind to a HLA molecule on the surface of the cancer cell of the human subject and has a HLA matched to the subject,
(iii) more than one peptide linker each comprising a peptide cleavage site cleavable by a tumor associated protease and
wherein each linker can be selectively cleaved by a tumor associated protease to release each T cell epitope in the vicinity of, and outside of, the solid tumor cells,
wherein each peptide linker is separately attached to the targeting moiety,
wherein each linker attaches a single T cell epitope to the targeting moiety, and
wherein the solid tumor is not a lymphoma.

2. The agent according to claim 1 , wherein at least some of the peptide cleavage sites are the same.

3. The agent according to claim 1 , wherein at least some of the peptide cleavage sites are not the same.

4. The agent according to claim 1 , wherein the tumor associated protease is Cathepsin B, Cathepsin L, Cathepsin S, Cathepsin D, Cathepsin E, Cathepsin A, Cathepsin G, Thrombin, Plasmin, Urokinase, Tissue Plasminogen Activator, Metalloproteinase 1 (MMP1), MMP2, MMP3, MMP4, MMP7, MMP8, MMP9, MMP10, MMP11, MMP12, MMP13, MMP14, MMP15, MMP16, MMP17, MMP20, MMP21, MMP23, MMP24, MMP25, MMP26, MMP28, ADAM, ADAMTS, CD10 (CALLA), or prostate specific antigen.

5. The agent according to claim 1 , wherein the more than one T cell epitopes are the same.

6. The agent according to claim 1 , wherein the more than one T cell epitopes are not the same.

7. The agent according to claim 1 , wherein one or more T cell epitope is from any of Varicella Zoster virus, Herpes simplex virus, cytomegalovirus, Epstein Barr virus, adenovirus, rhinovirus, or influenza virus.

8. The agent according to claim 1 , wherein one or more T cell epitope is an MHC Class I restricted antigen, an MHC Class II restricted antigen, or an antigen that is capable of binding to a group I CD1 molecule.

9. The agent of claim 1 , wherein one or more viral T cell epitope is one to which a number of T cells in the subject are already sensitized to.

10. The agent of claim 1 , wherein one or more viral T cell epitope is one that elicits an existing immune response, wherein the existing immune response has been generated by prior vaccination against an infectious agent.

11. The agent of claim 1 , wherein one or more viral T cell epitope is one that elicits an existing immune response, wherein the existing immune response has been generated by exposing the human subject's T cells to the epitope in vitro.

12. The agent of claim 1 , wherein the solid tumor is chosen from an epithelial tumor, prostate tumor, ovarian tumor, renal cell tumor, gastrointestinal tract tumor, hepatic tumor, colorectal tumor, tumor with vasculature, mesothelioma tumor, pancreatic tumor, breast tumor, sarcoma tumor, lung tumor, brain tumor, melanoma tumor, small cell lung tumor, neuroblastoma tumor, testicular tumor, carcinoma tumor, adenocarcinoma tumor, glioma tumor, seminoma tumor, or osteosarcoma tumor.

13. The agent according to claim 1 , wherein selective cleavage of each cleavage site enables release of each T cell epitope at or near to the cell surface of the solid tumor cells.

14. The agent according to claim 1 , wherein the antibody or antigen binding fragment thereof is specific for EpCAM (CD326).

15. The agent according to claim 1 , wherein the antibody or antigen binding fragment thereof is an anti-EpCAM antibody.

16. The agent according to claim 15 , wherein the antibody or antigen binding fragment thereof is an anti-CEA antibody.

17. The agent according to claim 1 , wherein the antibody or antigen binding fragment thereof is specific for CEACAM.

18. The agent according to claim 1 , wherein the antibody is Cetuximab.

19. A pharmaceutical composition, comprising an agent according to claim 1 , and a pharmaceutically acceptable carrier, diluent or excipient.

20. A composition comprising (i) an agent according to claim 1 and (ii) a therapeutic agent suitable for treating a solid tumor.

21. The agent according to claim 1 , wherein the antibody or antigen binding fragment thereof is specific for any of Her2; EGFR; PSMA; CD30; CD33; CD2; CA125; Carbonic Anhydrase IX; CD70; CD74; CD56; CD40; c met/HGFR; TRAIL R1; DR5; PD-1; PDL1; IGF-1R; VEGF-R2; Prostate stem cell antigen (PSCA); MUC1; CanAg; Mesothelin; P-cadherin; Myostatin (GDF8); Cripto (TDGF1); ACVRL1/ALK1; MUC5AC; CEACAM; SLC44A4; CD137; CXCR4; Neuropilin 1; Glypican; PDGFRa, EphA2, E-cadherin, FGFR3, EpCAM, and CD138.

22. The agent according to claim 1 , wherein the antibody or antigen binding fragment thereof is an anti-epidermal growth factor receptor antibody, an anti-Her2 antibody, an anti-MUC1 antibody, an anti-P-cadherin antibody, an anti-E-cadherin antibody, an anti-CEA antibody, or an anti-FGFR3 antibody.

Assignees

• Univ Birmingham

Inventors

• Cobbold Mark
• Millar David

Classifications

• A61K39/12 Primary

  Viral antigens · CPC title

• A61K47/6851

  the antibody targeting a determinant of a tumour cell · CPC title

• C07K16/2878

  against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95 · CPC title

• A61P25/00

  Drugs for disorders of the nervous system · CPC title

• A61K2039/627

  characterised by the linker · CPC title